Equillium
Yahoo Finance • 2 years ago
Equillium’s Partner Biocon Initiates Phase 2 Study of Itolizumab in Ulcerative Colitis
LA JOLLA, Calif., December 16, 2022--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that... Full story
Yahoo Finance • 2 years ago
Equillium Announces Presentation of Data Demonstrating Biological Importance of Multi-Cytokine Inhibitors EQ101 and EQ102 at the La Jolla Immunology Conference
Results demonstrate the use of selective inhibitors of multiple key cytokines as an effective strategy in treating autoimmune diseases driven by T and NK cells LA JOLLA, Calif., October 26, 2022--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq:... Full story
Yahoo Finance • 2 years ago
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates STR, MNRL, EQ, MTCR
NEW YORK, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to sharehold... Full story
Yahoo Finance • 3 years ago
Equillium to Present at Two Upcoming Investor Conferences
LA JOLLA, Calif., May 17, 2022--(BUSINESS WIRE)--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical ne... Full story
